Nilesh Talele, PhD
About Nilesh Talele, PhD
Nilesh Talele, PhD, serves as the Director of Business Development at Fortress Biotech, where he has worked since 2021. He has a strong background in oncology and immunology, with extensive experience in research and business development within the biotech sector.
Work at Fortress Biotech
Nilesh Talele has served as the Director of Business Development at Fortress Biotech since 2021. In this role, he has contributed to the company's strategic initiatives and business growth. His efforts have been instrumental in developing business strategies that align with the company's goals. Under his guidance, Fortress Biotech has been recognized in Deloitte’s Technology Fast 500™ rankings for two consecutive years, 2019 and 2020. His focus on partnerships and licensing has strengthened the company's position in the biotech sector.
Education and Expertise
Nilesh Talele holds a Doctor of Philosophy (PhD) in Stem Cell Biology from the University of Toronto, which he completed from 2010 to 2014. He also earned a Master of Science (MSc) in Stem Cell Technology from the University of Nottingham from 2008 to 2009, and a Bachelor of Science (BSc) in Biological and Biomedical Sciences from the University of Central Lancashire from 2005 to 2008. His educational background provides a strong foundation in biological sciences, with a specific emphasis on stem cell research.
Background
Before joining Fortress Biotech, Nilesh Talele accumulated extensive experience in various research and development roles. He worked as a Cancer Research Institute - Merck Research Fellow at Massachusetts General Hospital from 2017 to 2021. His previous positions include Research Fellow roles at Harvard Medical School and the Broad Institute, both from 2015 to 2021. He also served as a Postdoctoral Researcher at Massachusetts General Hospital from 2015 to 2017, and as an Early Stage Researcher at the University of Toronto from 2010 to 2015.
Achievements
Nilesh Talele has made significant contributions to the biotech industry, particularly in business development and research. He developed a hub-and-spoke model for venture creation, which has been influential in the biotech sector. His leadership in the discovery-to-commercialization phase of a startup company highlights his capability in bringing new biotech products to market. Additionally, he has a strong background in oncology, immunology, fibrosis, and cardiology, focusing on translational research and biomarker analysis.